Director

Patrick Machado has more than 20 years of experience in the biotechnology industry. He co-founded the U.S. biotechnology company, Medivation, Inc., which successfully developed and launched Xtandi^®, and served as its chief business officer and chief financial officer until his retirement in 2014 and then as a member of its board of directors until its acquisition by Pfizer in 2016.

Mr. Machado currently serves as chairman of the board for Prota Therapeutics and Adverum Biotechnologies. He also serves on the board of directors for ACELYRIN, Alumis, Arcus Biosciences and Xenon Pharmaceuticals. Mr. Machado has previously served on various other company boards across the U.S., Canada, Europe and Australia, including Turning Point Therapeutics, Principia Biopharma, Therachon, Endocyte and Roivant Sciences.

Mr. Machado earned a J.D. from Harvard Law School and a B.A. and B.S. in German and Economics, respectively, from Santa Clara University.